Navigation Links
Covance Elects Joseph C. Scodari to Company's Board of Directors
Date:5/8/2008

PRINCETON, N.J., May 8 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Joseph C. Scodari to its Board of Directors.

"We are very pleased to have Joe Scodari join our Board of Directors. He has enjoyed a distinguished 34-year career as a key leader in the pharmaceutical and biotechnology industries, and he has a proven track record of driving growth in large, complex global healthcare businesses," said Joe Herring, Covance chairman and CEO. "In addition, Mr. Scodari's expertise in strategy development and pharmaceutical R&D will help us further strengthen our large client partnerships and enhance our ability to provide productivity solutions that matter."

"Covance's market leadership and broad service offerings position it well to help pharmaceutical companies reduce the time and cost of drug development," Mr. Scodari said. "I look forward to working with Joe and the esteemed group of board members to take advantage of the significant market opportunities in the drug development services industry and continue to drive the company's growth."

Mr. Scodari was recently the worldwide chairman of the Johnson & Johnson (J&J) Pharmaceuticals Group. In this role, he led efforts to improve research and development productivity and build a more robust pipeline. He was also a member of the J&J executive committee and a corporate officer. Before Mr. Scodari was appointed worldwide chairman of J&J's pharmaceutical business in 2005, he was the company group chairman of J&J's global biopharmaceuticals business and was responsible for commercial activities in biotechnology and for specialty businesses in oncology and virology. Under his leadership, Tibotec Therapeutics launched PREZISTA(R) (darunavir), the company's first entry into the HIV market. Previously, Mr. Scodari served as company group chairman for the North America pharmaceuticals business, which included management responsibility for Ortho-McNeil, Janssen Pharmaceutica, and Janssen-Ortho Inc., Canada. Prior to these roles, he served as president and COO, and as a director of Centocor, Inc. and led the organization's transformation from a focus on research and development to a fully integrated biopharmaceutical company. Mr. Scodari has also held leadership positions in Rhone-Poulenc Rorer Pharmaceuticals and Sterling Drug, Inc.

Mr. Scodari recently served as the vice chairman of the board and member of the executive committee of the Biotechnology Industry Organization (BIO). He has also served on the Board of Overseers of the Robert Wood Johnson School of Medicine and on the Board of Trustees of The University of the Sciences in Philadelphia. He was also previously a member of the Board of Directors of Pharmacyclics, Inc., a biopharmaceutical company focused on therapies for cancer. He has a B.A. from Youngstown State University.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the UBS Global Life Sciences Conference
2. Covance Elects Dr. Gary E. Costley to Board of Directors
3. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
4. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
5. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
6. Covance and Care Partner on Rwanda Early Childhood Development Initiative
7. Wendel Barr Appointed Chief Operating Officer of Covance
8. Covance to Present at 26th Annual JPMorgan Healthcare Conference
9. Covance to Present at UBS Global Healthcare Services Conference
10. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
11. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: